PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀
Stocks in this Quantisnow insightHealth Care
Historical context for PYPD
Across the 16 sessions after earlier PYPD headlines, the stock closed higher 9 times and lower 7 times, with a median move of 1.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | PYPD | SPY |
|---|---|---|---|
| May 20, 2026 | PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference | +1.9% | +1.0% |
| May 13, 2026 | PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results | -7.5% | +0.6% |
| May 6, 2026 | PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026 | -0.4% | +1.4% |
| Apr 28, 2026 | PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting | -3.3% | -0.5% |
| Apr 13, 2026 | PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026 | +2.1% | +1.0% |
| Mar 31, 2026 | PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA | +4.0% | +2.9% |
Quantisnow market dataNASDAQ
PYPD
PolyPid Ltd.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Listed since
- 2020
Get push alerts for PYPD
Full PYPD profile on Quantisnow Follow PYPD and get a push notification the moment its next story breaks.